Cargando…

Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated With Disease Severity in COVID-19 Patients

Understanding of the basis for severity and fatal outcome of SARS-CoV-2 infection is of paramount importance for developing therapeutic options and identification of prognostic markers. So far, accumulation of neutrophils and increased levels of pro-inflammatory cytokines are associated with disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Shrivastava, Shubham, Chelluboina, Shweta, Jedge, Prashant, Doke, Purwa, Palkar, Sonali, Mishra, Akhilesh Chandra, Arankalle, Vidya A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566808/
https://www.ncbi.nlm.nih.gov/pubmed/34746027
http://dx.doi.org/10.3389/fcimb.2021.751232
_version_ 1784594095316926464
author Shrivastava, Shubham
Chelluboina, Shweta
Jedge, Prashant
Doke, Purwa
Palkar, Sonali
Mishra, Akhilesh Chandra
Arankalle, Vidya A.
author_facet Shrivastava, Shubham
Chelluboina, Shweta
Jedge, Prashant
Doke, Purwa
Palkar, Sonali
Mishra, Akhilesh Chandra
Arankalle, Vidya A.
author_sort Shrivastava, Shubham
collection PubMed
description Understanding of the basis for severity and fatal outcome of SARS-CoV-2 infection is of paramount importance for developing therapeutic options and identification of prognostic markers. So far, accumulation of neutrophils and increased levels of pro-inflammatory cytokines are associated with disease severity in COVID-19 patients. In this study, we aimed to compare circulatory levels of neutrophil secretory proteins, alpha-defensins (DEFA1), calprotectin (S100A8/A9), and myeloperoxidase (MPO) in COVID-19 patients with different clinical presentations. We studied 19 healthy subjects, 63 COVID-19 patients with mild (n=32) and severe (n=31) disease, 23 asymptomatic individuals identified through contact tracing programme and 23 recovering patients (1-4 months post-disease). At the time of disease presentation, serum levels of DEFA1 were significantly higher in patients with mild (mean230 ± 17, p<0.0001) and severe (mean452 ± 46, p<0.0001) disease respectively in comparison to healthy subjects (mean113 ± 11). S100A8/A9 proteins were significantly higher in COVID-19 patients (p<0.0001) irrespective of disease severity. The levels of DEFA1, S100A8/A9 and MPO reduced to normal in recovering patients and comparable to healthy subjects. Surprisingly, DEFA1 levels were higher in severe than mild patients in first week of onset of disease (p=0.004). Odds-ratio analysis showed that DEFA1 could act as potential biomarker in predicting disease severity (OR=11.34). In addition, levels of DEFA1 and S100A8/A9 were significantly higher in patients with fatal outcome (p=0.004 and p=0.03) respectively. The rise in DEFA1 levels was independent of secondary infections. In conclusion, our data suggest that induction of elevated levels of alpha-defensins and S100A8/A9 is associated with poor disease outcome in COVID-19 patients.
format Online
Article
Text
id pubmed-8566808
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85668082021-11-05 Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated With Disease Severity in COVID-19 Patients Shrivastava, Shubham Chelluboina, Shweta Jedge, Prashant Doke, Purwa Palkar, Sonali Mishra, Akhilesh Chandra Arankalle, Vidya A. Front Cell Infect Microbiol Cellular and Infection Microbiology Understanding of the basis for severity and fatal outcome of SARS-CoV-2 infection is of paramount importance for developing therapeutic options and identification of prognostic markers. So far, accumulation of neutrophils and increased levels of pro-inflammatory cytokines are associated with disease severity in COVID-19 patients. In this study, we aimed to compare circulatory levels of neutrophil secretory proteins, alpha-defensins (DEFA1), calprotectin (S100A8/A9), and myeloperoxidase (MPO) in COVID-19 patients with different clinical presentations. We studied 19 healthy subjects, 63 COVID-19 patients with mild (n=32) and severe (n=31) disease, 23 asymptomatic individuals identified through contact tracing programme and 23 recovering patients (1-4 months post-disease). At the time of disease presentation, serum levels of DEFA1 were significantly higher in patients with mild (mean230 ± 17, p<0.0001) and severe (mean452 ± 46, p<0.0001) disease respectively in comparison to healthy subjects (mean113 ± 11). S100A8/A9 proteins were significantly higher in COVID-19 patients (p<0.0001) irrespective of disease severity. The levels of DEFA1, S100A8/A9 and MPO reduced to normal in recovering patients and comparable to healthy subjects. Surprisingly, DEFA1 levels were higher in severe than mild patients in first week of onset of disease (p=0.004). Odds-ratio analysis showed that DEFA1 could act as potential biomarker in predicting disease severity (OR=11.34). In addition, levels of DEFA1 and S100A8/A9 were significantly higher in patients with fatal outcome (p=0.004 and p=0.03) respectively. The rise in DEFA1 levels was independent of secondary infections. In conclusion, our data suggest that induction of elevated levels of alpha-defensins and S100A8/A9 is associated with poor disease outcome in COVID-19 patients. Frontiers Media S.A. 2021-10-21 /pmc/articles/PMC8566808/ /pubmed/34746027 http://dx.doi.org/10.3389/fcimb.2021.751232 Text en Copyright © 2021 Shrivastava, Chelluboina, Jedge, Doke, Palkar, Mishra and Arankalle https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Shrivastava, Shubham
Chelluboina, Shweta
Jedge, Prashant
Doke, Purwa
Palkar, Sonali
Mishra, Akhilesh Chandra
Arankalle, Vidya A.
Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated With Disease Severity in COVID-19 Patients
title Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated With Disease Severity in COVID-19 Patients
title_full Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated With Disease Severity in COVID-19 Patients
title_fullStr Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated With Disease Severity in COVID-19 Patients
title_full_unstemmed Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated With Disease Severity in COVID-19 Patients
title_short Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated With Disease Severity in COVID-19 Patients
title_sort elevated levels of neutrophil activated proteins, alpha-defensins (defa1), calprotectin (s100a8/a9) and myeloperoxidase (mpo) are associated with disease severity in covid-19 patients
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566808/
https://www.ncbi.nlm.nih.gov/pubmed/34746027
http://dx.doi.org/10.3389/fcimb.2021.751232
work_keys_str_mv AT shrivastavashubham elevatedlevelsofneutrophilactivatedproteinsalphadefensinsdefa1calprotectins100a8a9andmyeloperoxidasempoareassociatedwithdiseaseseverityincovid19patients
AT chelluboinashweta elevatedlevelsofneutrophilactivatedproteinsalphadefensinsdefa1calprotectins100a8a9andmyeloperoxidasempoareassociatedwithdiseaseseverityincovid19patients
AT jedgeprashant elevatedlevelsofneutrophilactivatedproteinsalphadefensinsdefa1calprotectins100a8a9andmyeloperoxidasempoareassociatedwithdiseaseseverityincovid19patients
AT dokepurwa elevatedlevelsofneutrophilactivatedproteinsalphadefensinsdefa1calprotectins100a8a9andmyeloperoxidasempoareassociatedwithdiseaseseverityincovid19patients
AT palkarsonali elevatedlevelsofneutrophilactivatedproteinsalphadefensinsdefa1calprotectins100a8a9andmyeloperoxidasempoareassociatedwithdiseaseseverityincovid19patients
AT mishraakhileshchandra elevatedlevelsofneutrophilactivatedproteinsalphadefensinsdefa1calprotectins100a8a9andmyeloperoxidasempoareassociatedwithdiseaseseverityincovid19patients
AT arankallevidyaa elevatedlevelsofneutrophilactivatedproteinsalphadefensinsdefa1calprotectins100a8a9andmyeloperoxidasempoareassociatedwithdiseaseseverityincovid19patients